When is radioactive iodine (RAI) recommended for differentiated thyroid cancer?

When is RAI Recommended for Thyroid Cancers?

For differentiated thyroid cancer (DTC), radioactive iodine (RAI) is definitively recommended for high-risk patients and those with known residual or metastatic disease, generally recommended for intermediate-risk patients, optional for most low-risk patients except pT1a N0/NX where it should not be given, and contraindicated in very low-risk disease.

Risk-Stratified RAI Recommendations

Very Low-Risk (pT1a, N0/NX)

• No RAI should be administered 1
• These patients have excellent prognosis without RAI therapy
• Treatment would expose patients to unnecessary risks without survival benefit

Low-Risk (Other Low-Risk Features)

• RAI is optional and should be individualized 1
• If given, favor 30 mCi (1.1 GBq) with rhTSH stimulation 1
• The 2019 ESMO guidelines acknowledge controversy here: while 2015 ATA guidelines advised against routine RAI, the European Association of Nuclear Medicine (EANM) has not endorsed this recommendation due to lack of prospective RCT data proving surveillance is non-inferior 1
• Recent 2025 data suggests even in low-risk minimally invasive follicular thyroid cancer, there may be a 2.0% improvement in 10-year relative survival with RAI (though this only trended toward significance, P=0.055) 2

Decision factors when RAI is optional:

• Tumor features (size, multifocality, aggressive histology)
• Patient factors (age, comorbidities, anxiety level)
• Healthcare setting quality (surgeon expertise, ultrasound availability, thyroglobulin assay reliability)
• Expected benefits must outweigh risks (adverse events, quality of life impact) 1

Intermediate-Risk

• RAI is generally recommended 1
• Dose: 30-100 mCi (1.1-3.7 GBq) with either rhTSH or levothyroxine withdrawal 1
• For classical papillary thyroid cancer with larger tumor size or lymph node involvement, RAI provides 1.3-2.0% improvement in 10-year relative survival 2
• Timing matters: RAI delayed beyond 6 months post-surgery is associated with lower odds of excellent response (adjusted OR 1.98,95% CI 1.05-3.74) 3
• Greatest benefit observed in patients with 2 intermediate risk factors 4

High-Risk

• RAI is definitively indicated 1
• Dose: ≥100 mCi (3.7 GBq) with rhTSH or withdrawal 1
• High-risk DTC shows survival benefits up to 30.9% with RAI therapy 2

Known Residual or Metastatic Disease

• RAI is definitively indicated 1
• Dose: 100-200 mCi (3.7-7.4 GBq) with levothyroxine withdrawal 1
• Repeat RAI every 6-12 months as long as RAI uptake persists 1
• Perform cross-sectional imaging between administrations to ensure efficacy
• Caution: Cumulative doses exceeding 37.0 GBq (1,000 mCi) carry increased risk of secondary primary malignancies and long-term toxicity 5

RAI-Refractory Disease

Stop RAI and consider systemic therapy when:

• No RAI uptake is demonstrated on imaging
• Disease progresses despite RAI uptake (20% increase in target lesions or new lesions by RECIST criteria) 1
• Other controversial criteria: high FDG uptake, aggressive histology, persistence after several RAI courses 1

For RAI-refractory DTC that is clinically progressive or symptomatic, kinase inhibitors (lenvatinib preferred per NCCN 2025) provide clinical benefit in 50-60% of patients for approximately 12-24 months 6. Traditional cytotoxic chemotherapy like doxorubicin has minimal efficacy and is not recommended 6.

Critical Caveats

Dose thresholds for secondary malignancy risk:

• Some studies suggest cumulative doses exceeding 5.6-7.4 GBq (150-200 mCi) may increase secondary primary malignancy risk 5
• However, no clearly defined dose threshold exists in current literature
• Exercise particular caution with cumulative doses >37.0 GBq (1,000 mCi) 5

Recent evidence evolution:

• The 2025 ESTIMABL2 and IoN trials suggest thyroidectomy followed by surveillance alone may be sufficient in low-risk DTC 7
• However, 2025 SEER data shows even in low-risk disease, certain subgroups (lymph node involvement, larger tumors) derive survival benefit from RAI 2
• This highlights biological heterogeneity within risk categories and supports moving beyond simple risk classification 8

Preparation methods:

• Low activities (30 mCi) following rhTSH and high activities (100 mCi) following levothyroxine withdrawal are equally effective for successful ablation in low-risk populations 1
• This equivalence extends to recurrence-free survival 1